Vilaprisan (BAY1002670)
Drug2 mg tablet, single dose, oral administration
NCT Number: NCT03092999
Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Phase 1
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all subjects:
This is not required if safe contraception is achieved by a permanent method, such as hysterectomy, bilateral fallopian tube ligation or vasectomy.
For subjects with hepatic impairment:
Exclusion criteria
2 mg tablet, single dose, oral administration
Time frame: At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days
Exposure of Vilaprisan in plasma following a single dose administration
Time frame: At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days
Maximum observed (unbound) drug concentration (Cmax,u) in measured matrix after a single dose administration
Time frame: Up to 20 days
Frequency of Treatment Emergent Adverse Events as a measure of safety and tolerability
Time frame: Up to 20 days
The intensity of an AE is classified according to the following categories:
Time frame: Up to 20 days
Changes in blood laboratory parameters including hematology, clotting status, serum chemistry
Time frame: Up to 20 days
Changes in urine laboratory parameters including urine analysis, urine pregnancy tests
Time frame: Up to 20 days
Changes in Vital Signs, including blood pressure, pulse, body temperature
Time frame: Up to 20 days
ECG (12-lead) after ≥10 minutes supine rest
Bayer
Industry
Investigation of Pharmacokinetics, Safety, and Tolerability of Vilaprisan (BAY1002670) in Subjects With Hepatic Impairment (Classified as Child-Pugh A or B) Compared to Sex, Age, and Weight-matched Healthy Subjects Following a Single Oral Dose
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04655144
Leiomyoma, Neoplasms
Miami, Florida, United States
View Trial DetailsNCT04145518
Dysmenorrhea, Dysmenorrhea (Disorder)
Evanston, Illinois, United States
View Trial DetailsNCT02577055
Leiomyoma, Neoplasms
Montpellier, France
View Trial DetailsNCT02777203
Leiomyoma, Neoplasms
Park Ridge, Illinois, United States
View Trial Details